Page last updated: 2024-11-08

2-(4-fluorobenzoylamino)benzoic acid methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-fluorobenzoylamino)benzoic acid methyl ester: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID310557
CHEMBL ID250428
CHEBI ID93386
SCHEMBL ID4459274
MeSH IDM0569538

Synonyms (58)

Synonym
HMS3268K08
BRD-K78633253-001-01-2
nsc-214045
nsc214045
75541-83-2
exo 1, >=98% (hplc), solid
methyl 2-[(4-fluorobenzoyl)amino]benzoate
smr000304795
MLS000722799
ml084
CBDIVE_001626
NCGC00025310-01
HSCI1_000065
OPREA1_575828
PROBES1_000314
EU-0002175
PROBES1_000442
PROBES2_000515
exo1
2-(4-fluorobenzoylamino)benzoic acid methyl ester
PROBES1_000309
PROBES2_000388
NCGC00025310-02
methyl 2-(4-fluorobenzamido)benzoate
CHEMBL250428
AKOS000453340
methyl 2-{[(4-fluorophenyl)carbonyl]amino}benzoate
STK514439
FT-0644702
HMS2757J19
exo 1
461681-88-9
S6800
SCHEMBL4459274
exo-1
2-[(4-fluorobenzoyl)amino]-benzoic acid methyl ester
HMS3428E09
CHEBI:93386
SR-01000405814-2
sr-01000405814
SR-01000405814-1
CS-0059209
HY-112670
2-[(4-fluorobenzoyl)amino]benzoic acid methyl ester
DTXSID90893483
Q27165089
2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester
Z27655994
HMS3676L04
HMS3412L04
BRD-K78633253-001-04-6
BCP29874
exo-1; exo 1
exocytic inhibitor 1;2-[(4-fluorobenzoyl)amino]benzoic acid methyl ester
MS-23874
benzoic acid, 2-[(4-fluorobenzoyl)amino]-, methyl ester
methyl2-[(4-fluorobenzoyl)amino]benzoate
EN300-6492988
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency53.17640.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency5.62340.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency14.58100.000811.382244.6684AID686979
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency5.01190.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID305968Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
AID305970Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
AID305971Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
AID305969Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's5 (45.45)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.01 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]